Enasidenib combination therapy boosts remission in acute myeloid leukemia patients

Written by Heather Jones, Future Science Group

A Phase II study led by The University of Texas MD Anderson Cancer Center (TX, USA) has demonstrated that combining standard chemotherapy azacitidine (AZA) with enasidenib (ENA) improves remission rates in patients newly diagnosed with a specific form of acute myeloid leukemia (AML). The results of the study were presented at the American Society of Hematology Annual Meeting & Exposition (7–10 December, FL, USA). “This study looked at AML involving mutations in a gene known as isocitrate dehydrogenase or IDH2,” commented Courtney DiNardo from The University of Texas. “IDH2 mutations occur in 8% to 19% of patients with AML. This...

To view this content, please register now for access

It's completely free